As of November 6, 2026, Silence Therapeutics plc is a publicly traded company (Nasdaq: SLN). The largest holder reporting an active stake on Schedule 13D is Richard Griffiths, at 7.97%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Fidelity (FMR) (7.1%), Raymond Debbane (7%), Tetragon Financial Group Limited (5.2%) (Schedule 13D/A, August 13, 2026).
Is this your company?
About to sign with, pay or invest in Silence Therapeutics plc? See the free Snapshot first.
Free to see. No signup.
Is Silence Therapeutics plc a real, registered company?
- Silence Therapeutics plc files with the SEC under CIK 1479615 (its SEC filings).
- Its shares are listed under the ticker SLN on Nasdaq (also SLNCF) (SEC company record).
- Incorporated in X0, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under SILENCE THERAPEUTICS PLC in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Fidelity (FMR) (filed 2026-11-05).
Who are Silence Therapeutics plc's owners and officers?
Silence Therapeutics plc: industry Pharmaceutical Preparations (Schedule 13G, 2026-11-05).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-11-05 | Fmr LLC | 7.1% |
| Schedule 13G, 2026-10-13 | Tetragon Financial Group Limited | 5.2% |
| Schedule 13G/A, 2026-10-13 | Tetragon Financial Group Limited | 5.3% |
| Schedule 13D/A, 2026-08-13 | Richard Griffiths | 7.97% |
| Schedule 13G/A, 2026-08-13 | Raymond Debbane | 7% |
| Schedule 13D/A, 2026-07-08 | Richard Griffiths | 21.7% |
| Schedule 13G/A, 2026-02-09 | Lombard Odier Asset Management (USA) Corp | 4.2% |
Questions about who owns Silence Therapeutics plc
Who owns Silence Therapeutics plc?
On this page, 4 holders' latest ownership filings report 5% or more of Silence Therapeutics plc: Richard Griffiths (7.97%, Schedule 13D/A, filed 2026-08-13), Fmr LLC (7.1%, Schedule 13G, filed 2026-11-05), Raymond Debbane (7%, Schedule 13G/A, filed 2026-08-13) and Tetragon Financial Group Limited (5.2%, Schedule 13G, filed 2026-10-13).
Who are the largest shareholders of Silence Therapeutics plc?
By the share each holder's latest filing reports, the largest holders of Silence Therapeutics plc on this page are Richard Griffiths (7.97%), Fmr LLC (7.1%) and Raymond Debbane (7%).
When did Richard Griffiths buy into Silence Therapeutics plc?
The filings give report dates, not purchase dates. The earliest filing from Richard Griffiths on this page is the Schedule 13D/A, filed 2026-07-08, reporting 21.7%; its latest, Schedule 13D/A filed 2026-08-13, reports 7.97%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Silence Therapeutics plc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Silence Therapeutics plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Silence Therapeutics plc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Silence Therapeutics plc shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 39,942 shares (0.03% of shares outstanding) (Form 3, 2025-01-02).
- , the chief executive and president: 33,486 shares (0.02% of shares outstanding) (Form 3, 2025-01-02).
- , a director: 15,000 shares (0.01% of shares outstanding) (Form 3, 2025-12-22).
- , the executive vice president and chief r: 12,993 shares (0.01% of shares outstanding) (Form 3, 2025-01-02).
- , a director: 12,993 shares (0.01% of shares outstanding) (Form 3, 2025-01-02).
Shares outstanding: 141,740,037 as of 2026-07-31, from the company's latest SEC cover page.
How much has Silence Therapeutics plc raised?
No fundraising or offering filing from Silence Therapeutics plc is on file with us.
Keep reading
More on Silence Therapeutics plc and the records around it.
Silence Therapeutics plc elsewhere on the record
- 5%+ stake filings Nov 2026
Companies that share a holder
- Invus Public Equities, L.P. also filed stake reports on 24 other companies: City Therapeutics, Inc. (Oct 2026), Yarrow Bioscience, Inc. (Sep 2026), Abivax S.A. (Aug 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/silence-therapeutics